Silencing of Gprasp1 or Gprasp2 enhances HSPC survival and quiescence. (A) Experimental schematic. (B-C) LSK cells transduced with Gprasp1, Gprasp2, or control shRNAs were assayed by flow cytometry: (B) for (i) apoptosis or (ii) cell cycle status; (C) for (i) expansion, (ii) viability, or (iii) carboxyfluorescein succinimidyl ester (CFSE) retention. (D) Experimental schematic. CD45.2⁺ LSK cells transduced with Gprasp1, Gprasp2, or control shRNAs were transplanted into lethally irradiated CD45.1/CD45.2⁺ mice. Recipient CD45.2⁺mCherry⁺ HSPCs were analyzed for apoptosis (E) and cell cycle (F) 10 and 20 days posttransplant by flow cytometry. Data in panels E and F from 4 independent transplants with 5 recipients per condition per transplant. Data represented as mean plus or minus SEM. */#, P < .05; **/##, P < .005; ***/###, P < .001 relative to control. In panel C, * refers to Gprasp1 shRNA, # refers to Gprasp2 shRNA.